Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01319591 · ClinicalTrials.gov registry record
Comparison of Creatinine Clearance Calculation for Estimation of GFR in Patients Receiving HD Methotrexate
A clinical trial, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- 40
- Enrollment target
NCT01319591: Completed study, sponsored by Dana-Farber Cancer Institute.
NCT01319591 is a clinical trial that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01319591 has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to compare different estimates of calculating creatinine clearance by mathematical formula and compare them to creatinine clearance based on a timed urine collection in patients who received high-dose methotrexate for the treatment of primary CNS lymphoma or CNS involvement of systemic lymphoma.
Primary Outcome
Serum creatinine-based equations to be included in that analysis are: Cockcroft-Gault with the following weight descriptors; ideal body weight, actual body weight, and adjusted body weight; Modified MDRD; CKD-EPI.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2011-03 |
| Est. Completion | 2017-09-01 |
What the finished NCT01319591 record still lists
NCT01319591 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01319591 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01319591 about?
NCT01319591 is a clinical study titled "Comparison of Creatinine Clearance Calculation for Estimation of GFR in Patients Receiving HD Methotrexate". The purpose of this study is to compare different estimates of calculating creatinine clearance by mathematical formula and compare them to creatinine clearance based on a timed urine collection in patients who received high-dose methotrexate for the treatment of primary CNS lymphoma or CNS involvem...
What is the current status of trial NCT01319591?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2011-03. Estimated completion is 2017-09-01.
Who is sponsoring clinical trial NCT01319591?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia